Sanofi and Regeneron unveiled data on their jointly developed drug for a difficult-to-treat chronic lung disorder that analysts say 'exceeded expectations.'
The more than 900 participants in the trial were current or former smokers, and those who received Dupixent showed improvements in lung function, quality of life and respiratory symptoms. Those results are a win for Dupixent as competing COPD drugs from drugmakers like AstraZeneca and GSK struggle to make successful strides toward approval.
"Change cannot come quick enough for people living with uncontrolled COPD but, unfortunately, many investigational treatments have failed to demonstrate significant clinical outcomes leaving these vulnerable patients with limited treatment options," said Dr. Dietmar Berger, Sanofi's chief medical officer, in a company press release.
The companies said a second phase three trial of Dupixent in COPD is ongoing, with data expected in 2024."This benefit suggests a clear clinically meaningful benefit for Dupixent and should support broad usage for the asset in this segment of the COPD market," Schott wrote in a research note to clients Thursday. He added that J.P. Morgan expects to see new COPD patients adding a $1.5 billion to $2 billion in new sales for Dupixent.sales of $8.
Cowen analyst Steve Scala shared a similar take on the new data, noting that COPD represents a major market opportunity for the drug. "We expect solid uptake for Dupixent once approved," he wrote in a note Thursday, adding that "we are strongly encouraged by positive data in COPD which could become a blockbuster opportunity for Dupixent and extend its growth trajectory through 2030+..."
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Sanofi, Regeneron unveil 'blow-out' smoker's lung drug dataSanofi's asthma and eczema drug Dupixent met all targets in a trial to treat 'smoker's lung', giving a major boost to the French drugmaker's growth prospects, but also underscoring a heavy reliance on its bestseller.
Consulte Mais informação »
Breakingviews - Pharma delivers, for othersRegeneron Pharmaceuticals and Sanofi have shown their blockbuster asthma and eczema drug, Dupixent, works unexpectedly well against chronic obstructive pulmonary disease (COPD). The progressive lung disease, which commonly crops up in heavy smokers, is the third biggest cause of death globally. A 30% reduction in exacerbations and significant lung function improvement means the drug should spin more profit. But like new and effective obesity drugs, a larger benefit will probably flow to society.
Consulte Mais informação »
Treat-to-Target or High-Intensity Statin in Clinical CAD?Some patients with side-effect concerns aiming to lessen their statin burden may prefer the treat-to-target approach, if they respond well to lesser-intensity statins, say researchers.
Consulte Mais informação »
Can an Addiction Drug Treat Long Covid?Doctors are prescribing low-dose naltrexone to treat the mysterious disease, even as studies into its efficacy continue.
Consulte Mais informação »
Democrats Introduce $300B Investment to Treat Housing as Human Right'In the richest country in the world, it is a moral imperative that we take this issue head-on,' said Rep. Pramila Jayapal.
Consulte Mais informação »
Rangers radio announcer Eric Nadel to miss start of season to treat mental health'I now find myself dealing with anxiety, insomnia and depression which are currently preventing me from doing the job I love. So, I regret to say I will not be in the broadcast booth when the season starts.' Nadel said in a statement.
Consulte Mais informação »